Anaphylaxis

Anaphylaxis is a serious systemic hypersensitivity reaction that usually develops rapidly and can be fatal. It commonly affects several organ systems, including the skin, respiratory tract, circulation, and gastrointestinal tract, although life-threatening reactions may occur without a rash. Anaphylactic shock is the circulatory-collapse form of anaphylaxis, not a synonym for every anaphylactic reaction. Diagnosis rests principally on the clinical presentation and circumstances of exposure. (aaaai.org)

Foods, medicines, and insect venoms are important triggers. Many reactions involve allergen-specific antibodies and activation of mast cells and basophils, which release histamine and other inflammatory mediators; other reactions arise through different pathways. These mechanisms connect anaphylaxis with allergy, the immune system, and the physiology of airway obstruction and circulatory failure. (pmc.ncbi.nlm.nih.gov)

Anaphylaxis is medically important because its progression can be rapid and unpredictable. Epinephrine, also called adrenaline, is the principal first-line treatment described in clinical guidelines. Understanding the condition encompasses its biological mechanisms, triggers, clinical patterns, diagnostic criteria, emergency treatment, subsequent investigation, and population burden. (resus.org.uk)

Definition, Terminology, and Clinical Boundaries

Anaphylaxis is a serious systemic hypersensitivity reaction that usually develops rapidly and may cause death. The World Allergy Organization’s (WAO) 2020 definition distinguishes this syndrome from severe anaphylaxis, in which the airway, breathing, or circulation is potentially compromised in a life-threatening manner. Neither circulatory shock nor typical skin findings are essential to the definition. “Systemic” does not mean that every organ must be affected: a reaction dominated by severe airway involvement can constitute anaphylaxis. The term identifies a clinical syndrome rather than a single immunological mechanism. (pmc.ncbi.nlm.nih.gov)

Sensitization is distinct from both clinical allergy and anaphylaxis. In IgE-mediated allergy, sensitization denotes the presence of allergen-specific immunoglobulin E, an antibody class; this can occur without symptoms when the substance is encountered. The 2010 US National Institute of Allergy and Infectious Diseases–sponsored food-allergy guidelines therefore require both sensitization and compatible symptoms on exposure to establish IgE-mediated food allergy. For example, a positive peanut-specific IgE result in someone who eats peanut without symptoms establishes sensitization, not a clinical allergic reaction and not anaphylaxis. Anaphylaxis describes an episode of illness, not a positive laboratory result or an underlying predisposition. (pmc.ncbi.nlm.nih.gov)

Localized allergy and isolated urticaria also fall outside the syndrome. A limited reaction at an exposure site is not equivalent to a serious systemic reaction. Generalized hives may involve skin far from the exposure site and thus be systemic in distribution, but hives alone do not establish anaphylaxis. Conversely, the absence of hives does not exclude it: the WAO guidance reports that skin signs are absent in approximately 10–20% of reactions. Its clinical boundaries include combinations such as skin or mucosal involvement with significant respiratory, circulatory, or severe gastrointestinal symptoms; relevant airway or circulatory compromise can also occur without skin involvement. These distinctions prevent “systemic allergic reaction” and “anaphylaxis” from being treated as interchangeable labels. (pmc.ncbi.nlm.nih.gov)

Anaphylactic shock is the circulatory-failure presentation of anaphylaxis, not a synonym for all anaphylaxis. It involves inadequate tissue perfusion associated with the reaction’s cardiovascular effects, including vasodilation, increased vascular permeability, and reduced venous return. A reaction with severe bronchospasm or laryngeal obstruction may be anaphylaxis even when blood pressure remains preserved and circulatory collapse has not occurred. Conversely, collapse is not needed to distinguish anaphylaxis from a less extensive allergic reaction. Resuscitation Council UK’s 2021 guidance explicitly recognizes that reduced venous return can occur even without obvious circulatory compromise, including in reactions dominated by severe bronchospasm. (pmc.ncbi.nlm.nih.gov)

“Anaphylactoid reaction” historically designated an anaphylaxis-like event thought to occur independently of IgE, whereas “anaphylactic” was reserved for IgE-dependent reactions. This distinction has largely been superseded because the clinical presentations are indistinguishable and the older label does not identify a specific alternative mechanism. WAO terminology instead distinguishes IgE-mediated anaphylaxis, non-IgE-mediated immunological anaphylaxis, and nonimmunological anaphylaxis. These categories separate, for example, antibody-dependent reactions from other immune pathways and direct mast-cell activation; “non-IgE-mediated” therefore does not necessarily mean “nonimmunological.” The underlying pathway is a mechanistic classification, whereas anaphylaxis remains the clinical designation regardless of that pathway. (pmc.ncbi.nlm.nih.gov)

Biological Mechanisms

In IgE-mediated anaphylaxis, sensitization precedes the acute reaction. During this process, B lymphocytes undergo antibody class switching and produce allergen-specific immunoglobulin E (IgE), supported by helper-T-cell signals, including interleukin-4 and interleukin-13. IgE binds through its Fc region to the high-affinity receptor FcεRI on tissue-resident mast cells and circulating basophils. This binding prepares the cells to respond but does not itself constitute anaphylaxis. On subsequent exposure, an allergen bearing multiple accessible binding sites can cross-link receptor-bound IgE molecules, aggregating FcεRI. Intracellular signaling, including increased cytoplasmic calcium, then triggers degranulation and the synthesis of additional inflammatory mediators. Mast cells are positioned near blood vessels and mucosal surfaces, allowing their products to affect vascular and airway function rapidly. (pmc.ncbi.nlm.nih.gov)

IgE-independent pathways can converge on similar mediator release. Activation of the complement system generates the fragments C3a and C5a, termed anaphylatoxins, which can activate responsive mast cells and other inflammatory cells. Complement activation has been associated with some infusion reactions, including reactions to liposomal medicines. Human studies have detected complement activation during anaphylaxis, but these observations do not establish complement as the initiating mechanism in every case. Another pathway involves IgG–antigen complexes activating Fcγ receptors on inflammatory cells. In 2019, Friederike Jönsson and colleagues studied 86 patients with suspected neuromuscular-blocking-agent anaphylaxis during anesthesia and 86 matched controls. Drug-specific IgG, neutrophil activation, and platelet-activating-factor release were associated with severity; purified patient IgG also activated neutrophils in the presence of the implicated drug outside the body. These findings support an IgG–neutrophil contribution in this setting, rather than a universal alternative to IgE. (pmc.ncbi.nlm.nih.gov)

Direct mast-cell activation does not require allergen-specific antibodies. The receptor MRGPRX2 responds to certain positively charged substances, including some opioids, fluoroquinolone antibiotics, and neuromuscular-blocking agents. Benjamin McNeil and colleagues’ 2015 experiments identified the corresponding mouse receptor, Mrgprb2: disrupting it markedly reduced secretagogue-induced histamine release and drug-associated reactions in mice. The study also demonstrated activation of human MRGPRX2 by selected drugs. However, receptor activation in laboratory preparations and protection in genetically modified mice do not by themselves prove that a particular human episode was MRGPRX2-mediated. IgE-dependent and direct-activation mechanisms may be difficult to distinguish from their clinical manifestations alone. (pubmed.ncbi.nlm.nih.gov)

The mediator mixture includes both preformed granule contents and newly synthesized lipids. Histamine is released rapidly from mast cells and basophils; through H1 receptors it promotes endothelial leakage and airway smooth-muscle contraction, while vascular H1 and H2 effects contribute to vasodilation. Cysteinyl leukotrienes—LTC4, LTD4, and LTE4—are synthesized after activation and promote bronchoconstriction, mucus secretion, and increased vascular permeability. Mast-cell-derived prostaglandin D2 can constrict human airways and alter vascular tone. These lipid mediators are not interchangeable: their effects depend on receptor distribution and tissue context, and experimental work has also identified protective effects of prostaglandin D2 in some mouse models. (pmc.ncbi.nlm.nih.gov)

Platelet-activating factor (PAF), a phospholipid mediator produced by several inflammatory cell types, contributes to vascular leakage, vasodilation, and bronchoconstriction. Despite its name, its effects extend beyond platelet activation. In a 2008 study, Peter Vadas and colleagues measured serum PAF in 41 patients with anaphylaxis and 23 controls: mean concentrations were $805 \pm 595$ versus $127 \pm 104$ pg/mL, respectively. Higher PAF concentrations and lower activity of PAF acetylhydrolase, the enzyme that inactivates PAF, correlated with greater reaction severity. These associations support a role in human anaphylaxis without establishing PAF as the sole determinant of severity. (pmc.ncbi.nlm.nih.gov)

Together, mediator-induced endothelial leakage moves plasma into tissues, producing edema while reducing intravascular volume. Arterial dilation lowers vascular resistance, and venous dilation reduces blood return to the heart; combined with plasma loss, this can decrease cardiac filling, cardiac output, and organ perfusion. In the respiratory tract, mucosal swelling narrows the upper airway, while smooth-muscle contraction narrows the bronchi. Reduced ventilation can therefore coincide with impaired circulation, compromising oxygen delivery through two distinct physiological routes. Direct cardiac effects of mediators can further contribute to cardiovascular dysfunction. (pmc.ncbi.nlm.nih.gov)

Triggers and Exposure Patterns

Food triggers are usually encountered through ingestion, and their distribution varies with age and regional dietary exposure. Cow’s milk, hen’s egg, wheat, and peanut are prominent causes in children, particularly milk and egg in infancy and the preschool years. Peanut and tree nuts are major triggers among adults in North America and Australia, whereas shellfish is especially important in Asia. Other regional patterns include sesame in the Middle East, buckwheat in Korea, and plant foods containing lipid-transfer proteins, such as peach, in southern Europe. These patterns describe populations rather than a universal ranking of allergenic foods. The 2020 World Allergy Organization guidance therefore identifies age, geography, and local food exposure as essential context for interpreting suspected food-related reactions. (worldallergyorganizationjournal.org)

Medicines can trigger reactions after oral or parenteral administration; antibiotics, including beta-lactams, and nonsteroidal anti-inflammatory drugs are important categories. Medical exposures also include injected contrast agents, biological medicines, chemotherapy, and substances administered during anesthesia or surgery. Perioperative exposure is distinctive because several potential triggers may be administered in rapid succession, including antibiotics, neuromuscular blocking agents, antiseptics, and surgical dyes. In the United Kingdom’s sixth National Audit Project, published in 2018, investigators reviewed 266 reports of severe perioperative anaphylaxis collected over one year. Among 199 identified culprit agents, 94 were antibiotics, 65 neuromuscular blocking agents, 18 chlorhexidine, and nine Patent Blue dye. These counts describe that audit’s identified agents, not the probability of reaction to each exposure. (allsa.org)

Insect-associated reactions commonly follow venom injected by the sting of a bee, wasp, or fire ant; the relevant insects vary geographically. This exposure differs from ingesting food or receiving an intravenous medicine because the allergen is deposited directly into tissue by a sting. Natural-rubber latex provides another exposure pattern: allergenic proteins can contact skin or mucous membranes or reach the respiratory tract in airborne particles. Gloves and medical devices may therefore provide relevant exposures during healthcare procedures. Immediate latex allergy, which can produce systemic reactions, is distinct from irritant dermatitis and delayed allergic contact dermatitis associated with latex products. (pmc.ncbi.nlm.nih.gov)

Exercise-induced anaphylaxis occurs in association with physical activity, sometimes without an identified food trigger. In food-dependent exercise-induced anaphylaxis, activity follows ingestion of a relevant food within hours; typically, the food and exercise are tolerated separately, but their combination provokes a reaction. Wheat is a well-characterized example, with omega-5 gliadin recognized as a major allergenic component. Other implicated foods include shellfish, celery, cow’s milk, and peanut. Exercise acts as a cofactor rather than simply another ingested allergen. Proposed mechanisms include altered intestinal permeability and allergen absorption, but the precise contribution of these processes is not fully established. (pmc.ncbi.nlm.nih.gov)

Alpha-gal syndrome produces a distinctive delayed exposure pattern. The target is galactose-α-1,3-galactose, a carbohydrate present in non-primate mammalian tissues, rather than the proteins responsible for most conventional food allergies. Sensitization is associated with bites from certain ticks; in the United States, the strongest association is with the lone star tick. Reactions may follow beef, pork, lamb, or other mammalian products, including gelatin and, in some affected individuals, dairy products. Symptoms commonly begin two to six hours after ingestion, making the connection with an earlier meal less obvious. The delay is not universal across exposure routes: alpha-gal-containing injected medicines can provoke more rapid reactions. (stacks.cdc.gov)

Anaphylaxis is classified as idiopathic when investigation identifies no trigger. This designation does not establish that an episode occurred without an external exposure: previously unrecognized allergens, delayed alpha-gal reactions, or food–exercise combinations may explain some initially unexplained events. The 2020 World Allergy Organization guidance specifically identifies alpha-gal and omega-5 gliadin among allergens that can be overlooked and notes that mast-cell disorders may also warrant consideration in unexplained cases. (pmc.ncbi.nlm.nih.gov)

Clinical Manifestations and Temporal Patterns

Cutaneous and mucosal manifestations include flushing, generalized itching, urticaria—raised, itchy wheals—and angioedema, deeper swelling that may affect the lips, tongue, or uvula. These findings can accompany respiratory or circulatory compromise, but their absence does not exclude anaphylaxis: the World Allergy Organization’s 2020 guidance reports that skin signs are absent in approximately 10–20% of reactions. Conversely, isolated hives or swelling do not by themselves establish anaphylaxis. A presentation dominated by airway obstruction or circulatory collapse may occur without a visible rash. (pmc.ncbi.nlm.nih.gov)

Respiratory manifestations include breathing difficulty, cough, wheeze from bronchospasm, and hypoxemia, or reduced blood oxygen. Upper-airway involvement may produce throat tightness, a hoarse or altered voice, difficulty swallowing, and stridor—a harsh sound associated with narrowing of the upper airway. Laryngeal swelling can obstruct airflow, whereas bronchospasm principally affects the lower airways. Increasing respiratory effort, fatigue, cyanosis, or confusion can accompany severe breathing compromise. Respiratory and circulatory manifestations need not occur together; a reaction may be life-threatening because of airway or breathing impairment without hypotension. (pmc.ncbi.nlm.nih.gov)

Circulatory manifestations include hypotension, dizziness, collapse, fainting, and altered consciousness. Reduced cerebral perfusion may cause confusion or loss of consciousness; severe circulatory compromise can progress to cardiac arrest. Gastrointestinal involvement includes cramping abdominal pain, nausea, repetitive vomiting, and diarrhea. Symptoms usually develop over minutes to several hours, and may progress rapidly rather than appearing in a fixed sequence. The exposure route influences timing: injected medicines and insect stings generally produce a faster onset than ingested foods or medicines, although delayed-onset reactions also occur. (pmc.ncbi.nlm.nih.gov)

A monophasic course consists of one episode that resolves without subsequent recurrence. Biphasic anaphylaxis involves a second anaphylactic episode after complete resolution of the first, without renewed exposure to the trigger. In a 2020 multidisciplinary Delphi study led by Timothy E. Dribin, the consensus definition required an asymptomatic interval of at least one hour and recurrence within 48 hours of initial resolution. The recurrent episode must itself meet anaphylaxis criteria: isolated hives returning two hours after recovery constitute a biphasic nonanaphylactic allergic reaction, not necessarily biphasic anaphylaxis. The WAO guidance notes that approximately half of biphasic reactions occur within 6–12 hours. (pmc.ncbi.nlm.nih.gov)

Persistent anaphylaxis, sometimes termed protracted anaphylaxis, continues without complete resolution; the 2020 Delphi definition specifies findings meeting anaphylaxis criteria for at least four hours. Refractory anaphylaxis instead describes inadequate response to appropriate treatment, rather than a particular duration. The Delphi definition requires continuing anaphylaxis despite at least three appropriate epinephrine doses, or initiation of an intravenous epinephrine infusion, together with symptom-directed supportive management. The Resuscitation Council UK’s 2021 guidance uses an operational threshold of continuing respiratory or cardiovascular problems despite two appropriate intramuscular doses. These categories can overlap: an episode may be both persistent and refractory, or resolve and subsequently become biphasic. The consensus time thresholds classify clinical courses; they do not dictate treatment timing or observation duration. (pmc.ncbi.nlm.nih.gov)

Diagnosis and Differential Diagnosis

Anaphylaxis is a clinical diagnosis based on the onset, combination, and progression of findings in relation to a plausible exposure. Assessment establishes the exposure–symptom interval, examines airway and breathing, measures blood pressure, and looks for skin, mucosal, gastrointestinal, and neurological involvement. Laboratory testing supports this assessment but does not replace it. Diagnostic criteria identify patterns in which anaphylaxis is highly likely; they are not prerequisites for treating an evolving reaction. The 2023 practice parameter also distinguishes diagnosis from treatment response: administration of epinephrine, or improvement after it, does not by itself establish that anaphylaxis occurred. (pmc.ncbi.nlm.nih.gov)

The 2006 NIAID/FAAN criteria, published by Hugh Sampson and colleagues following a National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium, provide three alternative pathways. The first is acute skin or mucosal involvement together with respiratory compromise or reduced blood pressure/end-organ dysfunction. The second is rapid involvement of at least two of four categories—skin/mucosa, respiration, circulation, or persistent gastrointestinal symptoms—after exposure to a likely allergen. The third is reduced blood pressure after exposure to a known allergen. In adults, the blood-pressure criterion is systolic pressure below $90\ \mathrm{mmHg}$ or a decrease exceeding 30% from baseline; children have age-specific thresholds. These criteria were intended to standardize recognition across clinical settings and provide a common framework for research, rather than identify the underlying allergic mechanism. (pubmed.ncbi.nlm.nih.gov)

The 2020 World Allergy Organization criteria reduce these pathways to two. The first combines acute skin/mucosal involvement with respiratory compromise, circulatory compromise, or severe gastrointestinal symptoms, such as repetitive vomiting or severe cramping, especially after non-food allergens. The second recognizes acute hypotension, bronchospasm, or laryngeal involvement after a known or highly probable allergen for that patient, even without skin findings. Thus, isolated bronchospasm immediately after ingestion of a known food allergen can qualify, whereas bronchospasm from common inhaled allergens is excluded from this pathway. Laryngeal findings include stridor and voice change. Unlike the NIAID/FAAN framework, which already accommodates isolated hypotension after a known allergen, the WAO framework explicitly includes isolated airway involvement. Skin signs are absent in approximately 10–20% of reactions, making their absence an unreliable exclusion criterion. (pmc.ncbi.nlm.nih.gov)

Serum tryptase is a supportive biomarker of mast-cell activation. Concentrations generally peak one to two hours after symptom onset; the 2023 parameter specifies an acute sample as early as possible, ideally within two hours. A baseline sample is obtained after recovery, at least 24 hours after complete symptom resolution. A commonly used comparison is $T_{\mathrm{acute}}>1.2T_{\mathrm{baseline}}+2\ \mathrm{ng/mL}$, with both concentrations expressed in $\mathrm{ng/mL}$. This detects a relative rise rather than relying solely on the laboratory reference interval. A normal acute value does not exclude anaphylaxis, particularly food-induced reactions in children; sampling time and incomplete sensitivity also limit interpretation. An elevated baseline alone does not establish an acute episode. (pmc.ncbi.nlm.nih.gov)

Important mimics share individual findings but usually differ in their overall pattern. Vasovagal syncope typically involves pallor, sweating, and improvement when recumbent, without urticaria or respiratory compromise. Acute asthma causes wheeze and breathlessness but ordinarily not associated hives, angioedema, abdominal symptoms, or hypotension. Panic-associated symptoms can include breathlessness, flushing, tachycardia, and impending doom, but objective wheeze, swelling, and hypotension are unusual. These distinctions are probabilistic: absent skin signs do not settle the diagnosis. Hypovolemic, cardiogenic, and septic shock require consideration when circulatory collapse dominates, using the exposure history and accompanying findings to distinguish them. (worldallergyorganizationjournal.org)

Nonallergic angioedema can closely resemble anaphylactic airway swelling. Bradykinin-mediated forms include hereditary C1-inhibitor deficiency or dysfunction and angiotensin-converting enzyme inhibitor–associated angioedema. Recurrent swelling without wheals, abdominal attacks, family history, and relevant medication exposure help distinguish these conditions. For suspected hereditary C1-inhibitor–related disease, C4 concentration and C1-inhibitor antigenic and functional measurements provide a separate diagnostic pathway. Neither absence of wheals nor airway swelling alone identifies the mediator. (pmc.ncbi.nlm.nih.gov)

Clinical Severity and Associated Risk Factors

Severity is a continuum shaped by the exposure, the patient’s physiological reserve, and circumstances surrounding an episode, rather than a fixed property of a particular allergen. Allergen dose and route of exposure interact with immune responsiveness, comorbidities, and concurrent medicines. Diagnostic certainty and severity are separate dimensions: a reaction can clearly meet clinical diagnostic criteria without shock, whereas severe respiratory or circulatory compromise may occur without conspicuous skin findings. Severity grading describes the episode’s manifestations; it does not establish its mechanism or reliably predict the next episode. The 2023 practice parameter led by David B. K. Golden and Julie Wang emphasizes this multifactorial model. In food allergy, Paul Turner and colleagues’ 2022 evidence review found that previous reaction severity and allergen-specific antibody measurements were poor predictors of future severe reactions. (aaaai.org)

Age-related associations differ by trigger. Older age is associated with severe anaphylaxis overall, particularly in drug- and venom-associated reactions, whereas adolescents and young adults account disproportionately for severe food-associated outcomes. Cardiovascular disease can limit compensation for vasodilation and reduced circulating volume; chronic respiratory disease can reduce tolerance of bronchoconstriction and hypoxemia. Severe or uncontrolled asthma is a clinical concern, but an asthma diagnosis alone does not consistently distinguish people who will experience severe food reactions. Route also matters: injected medicines and insect venom enter tissues without the digestive processing involved in food ingestion. Drug etiology is associated with severe reactions, but neither injection nor membership in a particular trigger category determines an individual episode’s outcome. (pubmed.ncbi.nlm.nih.gov)

Mastocytosis and other clonal mast-cell disorders are particularly relevant to severe sting-associated or recurrent unexplained reactions. These disorders involve abnormal mast-cell populations and may produce profound hypotension or collapse without urticaria. In Margitta Worm and colleagues’ 2018 analysis of the European Anaphylaxis Registry, drawing on 122 centers in 11 countries, concomitant mastocytosis was associated with greater reaction severity, with an odds ratio of 3.1 and a reported confidence interval of 2.6–3.7. Such findings concern selected clinical populations, not the probability that every person with mastocytosis will develop severe anaphylaxis. A normal baseline tryptase concentration does not exclude an underlying clonal disorder. (pubmed.ncbi.nlm.nih.gov)

Hereditary alpha-tryptasemia is distinct from mastocytosis: it is an inherited trait involving increased copies of alpha-tryptase-encoding sequences at TPSAB1, usually accompanied by elevated basal serum tryptase. In a study published in 2021, Jonathan Lyons and colleagues found the trait in 7 of 125 healthy participants and 21 of 398 nonatopic controls. Among venom-allergic participants, it was associated with grade IV anaphylaxis, with a relative risk of 2.0. It can coexist with systemic mastocytosis, but its presence alone establishes neither a clonal disease nor inevitable severe reactions. These associations are strongest in selected venom-allergy and mast-cell-disorder cohorts and cannot automatically be extended to every trigger. (pubmed.ncbi.nlm.nih.gov)

Exercise, alcohol, intercurrent infection, and concurrent medicines may act as cofactors, changing the exposure threshold or severity rather than serving as the principal allergen. Exercise has a particularly well-documented role in food-dependent exercise-induced reactions; the 2018 European registry analysis also associated vigorous exercise with severe episodes, with an odds ratio of 1.5. Alcohol, infections, and nonsteroidal anti-inflammatory drugs are recognized potential modifiers, although their independent effects are less securely quantified and vary by trigger. A 2019 meta-analysis of observational studies covering 22,313 episodes found associations between severity and beta-blockers or angiotensin-converting enzyme inhibitors, with odds ratios of 2.19 and 1.56, respectively. The authors rated the evidence as low quality because underlying cardiovascular disease was inadequately controlled. These results therefore do not establish that the medicines themselves caused the increased severity. (pmc.ncbi.nlm.nih.gov)

Emergency Treatment and Observation

Epinephrine (adrenaline) is the first-line treatment in clinical guidelines because it acts simultaneously on the principal airway and circulatory disturbances. Alpha-adrenergic effects reverse peripheral vasodilation and reduce tissue swelling; beta-adrenergic effects increase myocardial contractility, dilate bronchial airways, and inhibit further mediator release. Resuscitation Council UK’s May 2021 guideline specifies intramuscular administration into the anterolateral thigh, even when intravenous access is available. This route avoids delays in obtaining vascular access and has a substantially safer adverse-effect profile than intravenous administration. Observational evidence associates delayed epinephrine treatment with prolonged reactions, hypotension, and fatal outcomes; randomized trials withholding epinephrine are absent. (resus.org.uk)

Professional care combines epinephrine with airway assessment, supplemental oxygen, assisted ventilation when necessary, and early specialist airway support for progressive obstruction. Intravenous crystalloid fluids address reduced circulating volume caused by vascular leakage and redistribution. Continuous electrocardiography, pulse oximetry, repeated blood-pressure measurements, and assessment of consciousness track deterioration and treatment response. Cardiac arrest requires cardiopulmonary resuscitation and advanced life support; intramuscular drug absorption is then unreliable, so resuscitation follows the intravenous or intraosseous approach used in cardiac-arrest protocols. (resus.org.uk)

Refractory reactions require escalation rather than substitution of less effective medicines. The 2021 UK framework defines refractory anaphylaxis as continuing respiratory or cardiovascular symptoms despite two appropriate intramuscular epinephrine doses. Specialist management uses a low-dose intravenous epinephrine infusion, titrated to clinical response with continuous physiological monitoring and concurrent fluid resuscitation. An infusion permits controlled adjustment of drug delivery; intravenous bolus administration carries greater risks of dosing errors, severe hypertension, arrhythmias, and myocardial ischemia. Intravenous epinephrine in patients with spontaneous circulation is therefore reserved for experienced specialists in appropriately monitored settings, rather than treated as interchangeable with intramuscular therapy. (pmc.ncbi.nlm.nih.gov)

Antihistamines have a limited symptomatic role: non-sedating oral agents can relieve persistent itching and urticaria after stabilization, but they do not reverse airway obstruction or circulatory compromise. Sedating agents can obscure assessment, and their administration must not delay epinephrine. Corticosteroids primarily modify later inflammatory responses, making an immediate effect on anaphylaxis biologically unlikely. The 2021 evidence update recommends against routine use, while allowing adjunctive use for selected refractory reactions or accompanying poorly controlled asthma. Neither drug class has reliable evidence of preventing biphasic reactions. Inhaled bronchodilators may relieve residual bronchospasm but do not treat shock or upper-airway swelling. (pmc.ncbi.nlm.nih.gov)

Observation after symptom resolution is risk-stratified because recurrence cannot be predicted reliably. Under the 2021 UK framework, selected patients may be considered for discharge after two hours if symptoms resolved completely following a rapid response to one promptly administered epinephrine dose, prescribed unused auto-injectors and training are already available, and adequate supervision is assured. At least six hours is recommended when two intramuscular doses were required or there is a previous biphasic reaction. At least twelve hours is specified for severe reactions requiring more than two doses, severe respiratory compromise or severe asthma, possible continuing allergen absorption, or circumstances limiting access to emergency care. These intervals run from symptom resolution, not initial exposure; they are clinical decision thresholds rather than guarantees against later recurrence. (pmc.ncbi.nlm.nih.gov)

Investigation After an Episode and Long-Term Clinical Management

Post-episode investigation reconstructs the chronology of exposure, symptoms, and treatment rather than assuming that the most recently encountered substance caused the reaction. An allergy-focused history records foods and their ingredients, prescribed and nonprescription medicines, insect stings, and the interval between each exposure and symptom onset. Exercise, alcohol, intercurrent illness, and medicines taken around a meal may help explain why a previously tolerated food was associated with a reaction on that occasion. Emergency records, witness descriptions, and laboratory results supplement the patient’s recollection. The World Allergy Organization’s 2020 guidance places specialist assessment of the cause alongside education and prevention of further episodes. (pmc.ncbi.nlm.nih.gov)

After a reaction during anesthesia or surgery, investigation requires the anesthetic chart and a timed inventory of administered drugs and other exposures, including antibiotics, neuromuscular blocking agents, antiseptics such as chlorhexidine, and latex. Several agents may have been given within minutes, so temporal proximity alone does not establish causation. Collaboration between allergy specialists and anesthesiologists connects test findings with plans for subsequent procedures. David B. K. Golden and colleagues’ 2023 practice parameter supports evaluation of all plausible perioperative culprits and relevant alternatives. It generally favors delaying immediate-hypersensitivity testing for 4–6 weeks, while allowing earlier investigation when another operation cannot be postponed; the evidence supporting this timing is of very low certainty. (eaaci.org)

Serum allergen-specific IgE measurements and skin-prick testing investigate sensitization to exposures suggested by the history. A positive result demonstrates allergen recognition by the immune system, not necessarily clinically relevant allergy or proof that the allergen caused the episode. Test performance varies with the substance and method: the 2023 European Academy of Allergy and Clinical Immunology food-allergy guideline identifies stronger diagnostic support for peanut and cashew testing than for some other foods, including wheat and soya. Tests against individual allergen components, such as peanut Ara h 2, can refine interpretation. Negative results also require clinical context; the 2011 World Allergy Organization guideline describes repeat testing weeks or months later when a convincing history conflicts with initially negative findings. (pubmed.ncbi.nlm.nih.gov)

Selected supervised challenge procedures address uncertainty that history and sensitization tests leave unresolved. An oral food challenge is the reference diagnostic procedure for confirming or excluding food allergy, including assessment of whether an established allergy has resolved. Because exposure can provoke a systemic reaction, challenges take place under medical supervision with appropriate treatment facilities. Drug challenges similarly assess clinical reactivity or tolerance to a candidate alternative. The 2024 EAACI/ENDA position paper uses risk stratification to determine the investigation pathway: omission of preliminary skin testing applies to defined low-risk situations, not automatically to patients with previous anaphylaxis. Skin tests are poorly validated for many medicines, including nonsteroidal anti-inflammatory drugs, and anesthetic challenges require highly specialized centers. (pubmed.ncbi.nlm.nih.gov)

Long-term care includes a documented trigger assessment, an individualized written emergency plan, and education about the prescribed epinephrine delivery device. Documentation distinguishes suspected from established causes and records the reaction, investigation results, and identified alternatives rather than leaving an undifferentiated drug-allergy label. Plans account for age, caregivers, school or workplace arrangements, comorbid disease, and likely exposure settings. Device education includes practical demonstration and confirmation that the patient or caregiver can use the specific product. The 2023 practice parameter treats the number of prescribed autoinjectors and instructions for contacting emergency services as individualized decisions; continuing follow-up revisits these arrangements. (pmc.ncbi.nlm.nih.gov)

Preventive treatment is trigger-specific. Venom immunotherapy uses repeated injections of the relevant insect venom to reduce the risk of systemic reactions to later stings in patients with an appropriate reaction history and demonstrated sensitization. The 2023 German–Austrian guideline describes a usual treatment duration of 3–5 years, with prolonged or permanent treatment considered in selected high-risk circumstances, including established mastocytosis or previous sting-associated cardiovascular or respiratory arrest. Suspected drug allergy instead requires identification of the culprit and suitable alternatives; supervised challenge may establish tolerance where uncertainty remains. These interventions target particular allergies or exposures and are not a universal treatment for all causes of anaphylaxis. (pmc.ncbi.nlm.nih.gov)

Epidemiology, Outcomes, and Health-System Burden

Incidence measures new cases or episodes per population-time, whereas lifetime prevalence measures the proportion of people who have ever experienced anaphylaxis. These estimates depend strongly on case definition. In Olmsted County, Minnesota, a medical-record linkage study covering 2001–2010 identified cases using the NIAID/FAAN clinical criteria and estimated an age- and sex-adjusted incidence of 42 per 100,000 person-years, standardized to the 2010 US white population. Food-associated incidence was highest among children aged 0–9 years, venom-associated incidence among adults aged 20–39, and medication-associated incidence among those aged 30–39. The county’s comparatively wealthy, less ethnically diverse population limits national generalization. Separately, a US telephone survey conducted during July–November 2011 among 1,000 adults estimated lifetime prevalence at 5.1% under its “probable” definition and 1.6% under its more stringent “very likely” definition. These symptom-based survey estimates are not interchangeable with clinically adjudicated incidence. (pmc.ncbi.nlm.nih.gov)

Hospitalization measures health-service use rather than all reactions occurring in a population. A UK national analysis of 1998–2018 admission records used ICD-10 codes T78.0, T78.2, and T88.6 for food-related, unspecified, and drug-related anaphylaxis. All-cause admission rates rose from 4.1 to 11.5 per 100,000 population annually; food-coded admissions rose from 1.23 to 4.04. Among children younger than 15 years, food-related admissions increased from 2.1 to 9.2 per 100,000 annually. Changes in recognition and admission policy can contribute to these trends: UK guidance introduced in 2011 recommended admission under pediatric care after emergency treatment of suspected anaphylaxis in children younger than 16. These admission rates cannot be directly compared with the Minnesota incidence estimate, which included clinically identified cases outside inpatient care. (bmj.com)

Population mortality and case fatality have different denominators. The UK study identified 152 probable food-anaphylaxis deaths during 1998–2018 through coronial findings and supporting information, including 120 confirmed at inquest. Population mortality was 0.009 per 100,000 in 1998 and 0.008 in 2018, despite rising admissions. Its admission-based fatality ratio therefore declined; this ratio is not the probability of death among all people experiencing a reaction, because community episodes and non-admitted emergency presentations are excluded from the denominator. Trigger patterns also differed by age: cow’s milk accounted for 17 of 66 food-anaphylaxis deaths among school-aged children in the study’s extended fatality dataset, which included deaths from 1992 onward. Population averages do not predict the outcome of an individual episode. (bmj.com)

Underrecognition and coding complicate surveillance. In the Minnesota investigation, reviewing records coded as food allergy, venom reactions, or medication adverse effects uncovered additional cases meeting clinical criteria. Conversely, ICD-10 labels referring to “anaphylactic shock” may be assigned to reactions without documented shock, so administrative codes alone cannot establish severity. Hospital datasets provide broad coverage of service use but omit reactions managed elsewhere; population surveys capture recalled experiences but depend on respondents’ interpretation of symptoms. Registries can collect more detailed triggers and outcomes, yet their availability is uneven: a World Allergy Organization survey published in 2023 received responses from 66 countries, with national anaphylaxis registries reported in only 11.3% of responding countries. (pmc.ncbi.nlm.nih.gov)

Recurrence adds longitudinal burden beyond the initial episode. A population-based follow-up study of 611 Olmsted County patients presenting during 2001–2010 documented 60 subsequent reactions in 50 patients, equivalent to 8% of patients and 2.6 recurrences per 100 person-years. These were later episodes, distinct from biphasic return of symptoms during one reaction. The burden on quality of life also includes fear during travel, restrictions on exercise and food-related activities, and bullying of food-allergic children, as documented in the 2020 World Allergy Organization guidance. (pubmed.ncbi.nlm.nih.gov)

Access to diagnosis and emergency medicines varies geographically and within health systems. In the 2023 World Allergy Organization survey, epinephrine autoinjectors were reported available in 60% of responding countries, predominantly high-income settings; some countries depended on individual importation. A US retrospective study of 342 patients with documented Hymenoptera venom allergy seen during 2019–2021 found autoinjector prescriptions in 27.4% of white patients and 15.6% of African American patients. Allergy-specialist referral was associated with substantially higher prescribing, although the observational design did not establish causation. This venom-allergy cohort was not restricted to anaphylaxis cases, but documents inequalities in access to evaluation and emergency medication within an important at-risk population. (worldallergyorganizationjournal.org)

Discovery and Development of Clinical Knowledge

Charles Richet and Paul Portier reported in 1902 that previous exposure to a substance could increase susceptibility to a subsequent dose rather than produce protection. Their research began with marine venoms: during a cruise organized by Prince Albert I of Monaco, they investigated Physalia, the Portuguese man-of-war; after returning to France, they used glycerol extracts of sea-anemone tentacles. Dogs surviving an initial injection sometimes developed rapidly fatal illness when injected again weeks later. Richet’s subsequent account described vomiting, bloody diarrhea, collapse, unconsciousness, and respiratory failure after doses previously tolerated. The important distinction was between the slowly developing toxicity of an initial injection and the rapid reaction following re-exposure. Their experiments established acquired hypersensitivity as an outcome distinct from protective immunity. (nobelprize.org)

Richet coined “anaphylaxis” in opposition to phylaxis, the Greek term for protection, to designate this increased susceptibility. He received the 1913 Nobel Prize in Physiology or Medicine for his work on anaphylaxis; Portier was not a joint recipient. In his Nobel lecture of December 11, 1913, Richet also described experiments from 1907 in which blood from a sensitized animal transferred susceptibility to another animal. This supported a circulating component, although his proposed sensitizing substance, “toxogenin,” was not a modern molecular explanation. Contemporary accounts instead distinguish allergen-specific IgE antibodies, activation of mast cells and basophils, and mediator release, while also recognizing pathways independent of IgE. The early experimental findings therefore remain historically important without making Richet’s interpretations equivalent to current mechanisms. (nobelprize.org)

Standardization of clinical recognition developed through multidisciplinary consensus. The US National Institute of Allergy and Infectious Diseases and Food Allergy and Anaphylaxis Network convened symposia in 2004 and 2005; the second report, led by Hugh A. Sampson and published in February 2006, brought together representatives of 16 organizations and government bodies. Its three alternative clinical criteria translated combinations of symptoms and exposure history into an operational aid to diagnosis. The World Allergy Organization incorporated this framework into its 2011 global guidelines, developed with contributions from more than 100 specialists on six continents. Its 2020 guidance reduced the framework to two alternatives and explicitly included acute hypotension, bronchospasm, or laryngeal involvement after a known or highly probable allergen exposure, even without skin findings. These changes addressed presentations that a predominantly multisystem model could overlook. (pmc.ncbi.nlm.nih.gov)

Clinical validation has remained distinct from agreement among experts. A prospective emergency-department study published in 2016 enrolled 174 patients evaluated for allergic reactions or possible anaphylaxis between April 2010 and March 2013. Against independent assessments by two allergist-immunologists, the NIAID/FAAN criteria had 95.1% sensitivity and 70.8% specificity. These findings supported their usefulness for recognition but also demonstrated that meeting the criteria did not invariably coincide with specialist classification. The reference standard was clinical judgment rather than an independently definitive laboratory test. A later GA2LEN consensus report, published in 2025 under the title “2024 consensus report,” identified the nonuniform adoption of the 2020 WAO criteria as a continuing source of inconsistency in care and research. (pubmed.ncbi.nlm.nih.gov)

Observational studies and registries have supplied evidence unavailable from individual experiments. The anaphylaxis registry in Germany, Austria, and Switzerland began collecting standardized specialist-center data in 2006; an analysis published in 2014 examined approximately 4,000 cases recorded through 2013. Such records connected suspected triggers, clinical manifestations, concomitant disease, investigation, and emergency treatment. They also documented differences between guideline recommendations and recorded care. Their limitations included retrospective reporting and incomplete emergency-treatment documentation. Laboratory research, meanwhile, has distinguished receptor-mediated cellular activation from alternative pathways, preventing the clinical syndrome from being treated as a single molecular process. (pmc.ncbi.nlm.nih.gov)

Guideline development increasingly separates recommendation strength from certainty of evidence. The Resuscitation Council UK’s 2021 evidence update used the GRADE evidence-to-decision framework to assess treatments systematically. Evidence supporting epinephrine included human observational studies, fatality registers, animal experiments, and pharmacokinetic studies conducted outside active reactions; trials comparing administration routes during anaphylaxis were absent. The difficulty of conducting randomized controlled trials during a potentially fatal emergency leaves important questions dependent on indirect evidence and expert consensus. The same review reassessed established adjunctive practices, including routine corticosteroid use, illustrating how evidence-based medicine can revise customary care without requiring a new discovery about the syndrome’s basic mechanism. (pmc.ncbi.nlm.nih.gov)

References

1. Emergency treatment of anaphylaxis: Guidelines for healthcare providersresus.org.uk
2. Epinephrine: The Drug of Choice for Anaphylaxis—A Statement of the World Allergy Organizationpmc.ncbi.nlm.nih.gov
3. World allergy organization anaphylaxis guidance 2020pmc.ncbi.nlm.nih.gov
4. The pathophysiology of anaphylaxispmc.ncbi.nlm.nih.gov
5. Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyondpmc.ncbi.nlm.nih.gov
6. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxispubmed.ncbi.nlm.nih.gov
7. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactionspubmed.ncbi.nlm.nih.gov
8. MRGPRX2 and Adverse Drug Reactionspmc.ncbi.nlm.nih.gov
9. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxispubmed.ncbi.nlm.nih.gov
10. World allergy organization anaphylaxis guidance 2020pmc.ncbi.nlm.nih.gov
11. World Allergy Organization Anaphylaxis Guidance 2020allsa.org
12. Latex Allergyallergy.org.au
13. Diagnosis and management of allergy and respiratory disorders in sport: An EAACI task force position paperpmc.ncbi.nlm.nih.gov
14. Alpha-gal syndrome (AGS) 2022 case definitionstacks.cdc.gov
15. Symptoms of Alpha-gal Syndromecdc.gov
16. Alpha-gal Syndrome (AGS) 2022 Case Definitionndc.services.cdc.gov
17. Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi studypmc.ncbi.nlm.nih.gov
18. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposiumpubmed.ncbi.nlm.nih.gov
19. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panelpmc.ncbi.nlm.nih.gov
20. Anaphylaxis: A 2023 practice parameter updateaaaai.org
21. World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxispmc.ncbi.nlm.nih.gov
22. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and updatepmc.ncbi.nlm.nih.gov
23. Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysispubmed.ncbi.nlm.nih.gov
24. Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registrypubmed.ncbi.nlm.nih.gov
25. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1pubmed.ncbi.nlm.nih.gov
26. Relationship Between Anaphylaxis and Use of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors: A Systematic Review and Meta-Analysis of Observational Studiespubmed.ncbi.nlm.nih.gov
27. Evidence update for the treatment of anaphylaxispmc.ncbi.nlm.nih.gov
28. Evidence update for the treatment of anaphylaxispmc.ncbi.nlm.nih.gov
29. Emergency treatment of anaphylaxis: concise clinical guidancepmc.ncbi.nlm.nih.gov
30. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactionseaaci.org
31. EAACI guidelines on the diagnosis of IgE-mediated food allergypubmed.ncbi.nlm.nih.gov
32. EAACI/ENDA position paper on drug provocation testingeaaci.org
33. Diagnosis and treatment of Hymenoptera venom allergy: S2k Guidelinepmc.ncbi.nlm.nih.gov
34. Trends, Characteristics and Incidence of Anaphylaxis in 2001–2010: A Population Based Studypmc.ncbi.nlm.nih.gov
35. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United Statespubmed.ncbi.nlm.nih.gov
36. Rate of recurrent anaphylaxis and associated risk factors among Olmsted County, Minnesota, residents: A population-based studypubmed.ncbi.nlm.nih.gov
37. Health disparities in hymenoptera venom allergy managementpubmed.ncbi.nlm.nih.gov
38. Charles Richet – Nobel Lecturenobelprize.org
39. 5 - La découverte de l’anaphylaxieoceano.org
40. The Nobel Prize in Physiology or Medicine 1913nobelprize.org
41. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposiumpubmed.ncbi.nlm.nih.gov
42. Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxispubmed.ncbi.nlm.nih.gov
43. Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA2LEN projectpubmed.ncbi.nlm.nih.gov
44. Triggers and Treatment of Anaphylaxis: An Analysis of 4000 Cases From Germany, Austria and Switzerlandpmc.ncbi.nlm.nih.gov